Brief: Immutep Announces Positive Final Data In 2nd Line Metastatic Nsclc Patients Refractory To Anti-Pd-(L)1 Therapy At European Lung Cancer Congress 2023

Immutep

31/03/2023 13:13

March 31 (Reuters) - Immutep Ltd  IMM.AX :
    * IMMUTEP ANNOUNCES POSITIVE FINAL DATA IN 2ND LINE
METASTATIC
NSCLC PATIENTS REFRACTORY TO ANTI-PD-(L)1 THERAPY AT EUROPEAN
LUNG CANCER CONGRESS 2023
    * IMMUTEP LTD - EFTI PLUS PEMBROLIZUMAB ACHIEVED MOS OF 9.9
MONTHS
AND A 39% OS RATE AT 21 MONTHS
    * IMMUTEP LTD - 83% OF PATIENTS STUDIED FOR TUMOUR GROWTH
KINETICS
SHOWED DECELERATION OF TUMOUR GROWTH OR SHRINKAGE OF TUMOURS
    * IMMUTEP LTD - ORR OF 8.3%, DCR OF 33.3%, AND 6-MONTH PFS
RATE OF
25% IN ALL-COMER PD-L1 PATIENT POPULATION
    * IMMUTEP LTD - ORR OF 33.3%, 6-MONTH PFS OF 50%, AND MOS
NOT YET
REACHED FOR PATIENTS WITH HIGH PD-L1 EXPRESSION
    * IMMUTEP LTD - COMBINATION OF EFTI PLUS PEMBROLIZUMAB WELL
TOLERATED IN DIFFICULT-TO-TREAT PATIENT POPULATION WITHOUT ANY
NEW SAFETY SIGNALS
    * IMMUTEP LTD - THERE WAS NO TREATMENT DISCONTINUATION DUE
TO
ADVERSE REACTIONS

Source text for Eikon:  ID:nGNX9MQYkg 
Further company coverage:  IMM.AX 

 ((Reutersbriefs@thomsonreuters.com;))